Bold Therapeutics announces that they will be attending and presenting at BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences.
Read more06-27-2022
Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 at the 2022 Metals in Medicine Gordon Research Conference.
05-10-2022
Bold Therapeutics is pleased to have been invited to present at Bio Korea 2022 as part of the Canadian trade delegation.
04-06-2022
Bold Therapeutics announced that it will present research supporting the use of BOLD-100 at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.
04-04-2022
Bold Therapeutics is excited to announce second place in the Innovator’s Pitch Challenge at the Digital Redefining Early-Stage Investments Conference.
03-10-2022
Bold Therapeutics successfully completed Phase 1b of its oncology trial of BOLD-100 combined with FOLFOX in the treatment of advanced gastrointestinal cancers.
01-13-2022
Bold Therapeutics announces an extension of the option agreement with Hana Pharm for development and commercialization rights to BOLD-100 in South Korea.
09-16-2021
Bold Therapeutics has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in an in vivo model of colorectal cancer.
07-07-2021
Bold Therapeutics announces the addition of U.S. Sites for its phase 1b / 2a trial of BOLD-100 in the treatment of advanced GI cancers.
06-23-2021
Bold Therapeutics is pleased to be collaborating with Dr. Stephen Barr at Western University to study BOLD-100 in the COVID-19 variants of concern.
06-09-2020
Bold Therapeutics announces it is receiving additional funding of up to CAD$965,000 from NRC IRAP to support the development of BOLD-100 as a novel antiviral.
05-11-2021
Bold Therapeutics announces that the U.S. Food & Drug Administration has granted BOLD-100 an Orphan Drug Designation in the treatment of gastric cancer.
04-16-2021
Bold Therapeutics announces that new research completed by collaborators shows BOLD-100 consistently reduced viral concentrations in COVID-19 variants.
04-09-2021
Dr. Van Schaeybroeck will present research supporting BOLD-100 as a potential anti-resistance therapy for BRAF-mutant colorectal cancer at AACR annual meeting.
01-08-2021
Bold Therapeutics announces that it is one of four companies selected to receive funding from the National Research Council of Canada for its COVID-19 research.
01-06-2021
Bold Therapeutics collaborators at University of Vienna published a study detailing the binding partners and mechanism of action of BOLD-100.
12-18-2020
Bold Therapeutics BOLD-100 program was one of only four COVID-19 therapeutics programs selected by the National Research Council for development support.
10-09-2020
Bold Therapeutics announced that the first patient for the company’s Phase 1b clinical trial has been enrolled at the Cross Cancer Institute.
09-17-2020
Georgetown University has recently published a new manuscript showing that Bold Therapeutics’ BOLD-100 has anti-cancer potential in breast cancer.
08-17-2020
Bold Therapeutics recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.
07-15-2020
Bold Therapeutics has in vitro data showing that its lead clinical-stage therapeutic, BOLD-100, successfully inhibits live SARS-CoV-2 (COVID-19).